AP NEWS

5-HT2C Antagonist - Pipeline Insight 2018 - ResearchAndMarkets.com

December 19, 2018

DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “5-HT2C Antagonist -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

‘5-HT2C Antagonist - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT2C Antagonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

ClinicalNon-clinicalInactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for 5-HT2C Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. 5-HT2C Antagonist - Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for 5-HT2C Antagonist

4. Comparative Analysis

5. 5-HT2C Antagonist Pipeline Products in Clinical Stages

6. 5-HT2C Antagonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

Pipeline Assessment by Route of AdministrationPipeline Assessment by Stage and Route of AdministrationPipeline Assessment by Molecule TypePipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

Companies Mentioned

Fabre-Kramer PharmaceuticalsSumitomo Dainippon PharmaAnaMar ABLundbeck A/SS1 PharmaceuticalsAltus Formulation IncServierJanssen-Cilag

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/lp8tts/5ht2c_antagonist?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005351/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL GENERAL HEALTH

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/19/2018 07:36 AM/DISC: 12/19/2018 07:36 AM

http://www.businesswire.com/news/home/20181219005351/en

AP RADIO
Update hourly